keyword
https://read.qxmd.com/read/38591617/enrichment-strategy-and-initial-characterization-of-heterodimers-enriched-from-a-co-formulated-cocktail-of-therapeutic-antibodies-against-sars-cov-2
#21
JOURNAL ARTICLE
Sophia Liu, Yuetian Yan, Cody M Secor, Zachary R Oberholtzer, Donna J Skow, Mushhood Sheikh, Youmi Moon, Yue Fu, Cristinel Sandu, Shunhai Wang, Ning Li, Jennifer B Nguyen, Michael P Rosconi, Erica A Pyles
Co-formulation of multiple drug products is an efficient and convenient approach to simultaneously deliver multiple biotherapeutics with the potentially added benefit of a synergistic therapeutic effect. However, co-formulation also increases the risk of heteromeric interactions, giving rise to unique impurities with unknown efficacy and immunogenicity. Therefore, it is critical to develop methods to evaluate the risk of heteromers as an impurity that could affect potency, efficacy, and/or immunogenicity. The most direct strategy to evaluate antibody heteromers is via specific enrichment...
2024: MAbs
https://read.qxmd.com/read/38585993/divergent-antibody-recognition-profiles-are-generated-by-protective-mrna-vaccines-against-marburg-and-ravn-viruses
#22
Alexander Bukreyev, Michelle Meyer, Bronwyn Gunn, Colette Pietzsch, Chandru Subramani, Erica Saphire, James Crowe, Galit Alter, Sunny Himansu, Andrea Carfi
The first-ever recent Marburg virus (MARV) outbreak in Ghana, West Africa and Equatorial Guinea has refocused efforts towards the development of therapeutics since no vaccine or treatment has been approved. mRNA vaccines were proven successful in a pandemic-response to severe acute respiratory syndrome coronavirus-2, making it an appealing vaccine platform to target highly pathogenic emerging viruses. Here, 1-methyl-pseudouridine-modified mRNA vaccines formulated in lipid nanoparticles (LNP) were developed against MARV and the closely-related Ravn virus (RAVV), which were based on sequences of the glycoproteins (GP) of the two viruses...
March 26, 2024: Research Square
https://read.qxmd.com/read/38585048/immunomodulatory-and-antioxidant-potential-of-polyherbal-dhatryadi-rasayana-in-the-form-of-churna-and-granules
#23
JOURNAL ARTICLE
Sheenam Rani, Usha Sharma, Manish Purushottam Deshmukh, Vipin Kumar, Khem Chand Sharma, Mayank Kumar Malik, Vetriselvan Subramaniyan
Dhatryadi Rasayana revitalizes the human body and helps in maintaining health with the elimination of ill effects of various diseases. The effective delivery systems for Rasayana may affect the profound effect of active principles in the body. The present study deals with investigation and evaluation of phytochemical constituents, physicochemical characteristics, along with antioxidant and immunomodulatory effects of Dhatryadi Rasayana in churna (powder) and granule formulations. Dhatryadi Rasayana churna and its granules were studied for various physicochemical parameters, e...
April 2, 2024: ACS Omega
https://read.qxmd.com/read/38584058/a-phase-iia-randomized-double-blind-safety-immunogenicity-and-efficacy-trial-of-plasmodium-falciparum-vaccine-antigens-merozoite-surface-protein-1-and-rts-s-formulated-with-as02-adjuvant-in-healthy-malaria-na%C3%A3-ve-adults
#24
JOURNAL ARTICLE
J F Cummings, M E Polhemus, K E Kester, C F Ockenhouse, R A Gasser, P Coyne, G Wortmann, R K Nielsen, K Schaecher, C A Holland, U Krzych, N Tornieporth, L A Soisson, E Angov, D G Heppner
BACKGROUND: To improve the efficacy of Plasmodium falciparum malaria vaccine RTS,S/AS02, we conducted a study in 2001 in healthy, malaria-naïve adults administered RTS,S/AS02 in combination with FMP1, a recombinant merozoite surface-protein-1, C-terminal 42kD fragment. METHODS: A double-blind Phase I/IIa study randomized N = 60 subjects 1:1:1:1 to one of four groups, N = 15/group, to evaluate safety, immunogenicity, and efficacy of intra-deltoid half-doses of RTS,S/AS02 and FMP1/AS02 administered in the contralateral (RTS,S + FMP1-separate) or same (RTS,S + FMP1-same) sites, or FMP1/AS02 alone (FMP1-alone), or RTS,S/AS02 alone (RTS,S-alone) on a 0-, 1-, 3-month schedule...
April 6, 2024: Vaccine
https://read.qxmd.com/read/38572979/concentration-dependent-diffusion-of-monoclonal-antibodies-underlying-mechanisms-of-anomalous-diffusion
#25
JOURNAL ARTICLE
Gaurav Kumar, Arezoo M Ardekani
The development, storage, transport, and subcutaneous delivery of highly concentrated monoclonal antibody formulations pose significant challenges due to the high solution viscosity and low diffusion of the antibody molecules in crowded environments. These issues often stem from the self-associating behavior of the antibody molecules, potentially leading to aggregation. In this work, we used a dissipative particle dynamics-based coarse-grained model to investigate the diffusion behavior of IgG1 antibody molecules in aqueous solutions with 15 and 32 mM NaCl and antibody concentrations ranging from 10 to 400 mg/mL...
April 4, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38570605/immunogenicity-and-efficacy-of-vla2001-vaccine-against-sars-cov-2-infection-in-male-cynomolgus-macaques
#26
JOURNAL ARTICLE
Mathilde Galhaut, Urban Lundberg, Romain Marlin, Robert Schlegl, Stefan Seidel, Ursula Bartuschka, Jürgen Heindl-Wruss, Francis Relouzat, Sébastien Langlois, Nathalie Dereuddre-Bosquet, Julie Morin, Maxence Galpin-Lebreau, Anne-Sophie Gallouët, Wesley Gros, Thibaut Naninck, Quentin Pascal, Catherine Chapon, Karine Mouchain, Guillaume Fichet, Julien Lemaitre, Mariangela Cavarelli, Vanessa Contreras, Nicolas Legrand, Andreas Meinke, Roger Le Grand
BACKGROUND: The fight against COVID-19 requires mass vaccination strategies, and vaccines inducing durable cross-protective responses are still needed. Inactivated vaccines have proven lasting efficacy against many pathogens and good safety records. They contain multiple protein antigens that may improve response breadth and can be easily adapted every year to maintain preparedness for future seasonally emerging variants. METHODS: The vaccine dose was determined using ELISA and pseudoviral particle-based neutralization assay in the mice...
April 3, 2024: Commun Med (Lond)
https://read.qxmd.com/read/38570417/novel-method-for-production-and-purification-of-untagged-pneumococcal-surface-protein-a-from-clade-1
#27
JOURNAL ARTICLE
Tasson da Costa Rodrigues, Patricia Zorzete, Eliane Namie Miyaji, Viviane Maimoni Gonçalves
Streptococcus pneumoniae can cause diseases with high mortality and morbidity. The licensed vaccines are based on capsular polysaccharides and induce antibodies with low cross reactivity, leading to restricted coverage of serotypes. For surpassing this limitation, new pneumococcal vaccines are needed for induction of broader protection. One important candidate is the pneumococcal surface protein A (PspA), which can be classified in 6 clades and 3 families. We have reported an efficient process for production and purification of untagged recombinant PspA from clade 4 (PspA4Pro)...
April 4, 2024: Applied Microbiology and Biotechnology
https://read.qxmd.com/read/38569976/enhancement-of-subunit-vaccine-delivery-with-zinc-carnosine-coordination-polymer-through-the-addition-of-mannan
#28
JOURNAL ARTICLE
John A Roque, Nicole Rose Lukesh, Dylan A Hendy, Timothy A Dixon, Md Jahirul Islam, Luis Ontiveros-Padilla, Erik S Pena, Liubov M Lifshits, Sean R Simpson, Cole J Batty, Eric M Bachelder, Kristy M Ainslie
Vaccines represent a pivotal health advancement for preventing infection. However, because carrier systems with repeated administration can invoke carrier-targeted immune responses that diminish subsequent immune responses (e.g., PEG antibodies), there is a continual need to develop novel vaccine platforms. Zinc carnosine microparticles (ZnCar MPs), which are composed of a one-dimensional coordination polymer formed between carnosine and the metal ion zinc, have exhibited efficacy in inducing an immune response against influenza...
April 1, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38567080/comparative-analysis-of-the-efficacy-of-vaccines-using-structural-protein-subunits-of-the-severe-fever-with-thrombocytopenia-syndrome-virus
#29
JOURNAL ARTICLE
Sohee Kim, Kyeongseok Jeon, Hooncheol Choi, Da-Eun Jeong, Jun-Gu Kang, Nam-Hyuk Cho
The severe fever with thrombocytopenia syndrome virus (SFTSV) represents a significant emerging health threat as a tick-borne pathogen that causes SFTS, with mortality rates ranging between 10 and 30%. Despite the considerable risk presented by SFTSV, an effective vaccine has yet to be developed. Our study assessed the efficacy of recombinant protein vaccines, focusing on the purified nucleocapsid protein (NP) and surface glycoproteins (Gn and Gc), against SFTSV in both singular and combined formulations. Individual vaccinations with NP or Gn subunits yielded partial protection in type I interferon receptor-knockout (IFNAR-KO) mice, with survival rates of 66...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38562934/profiling-antibody-epitopes-induced-by-mrna-1273-vaccination-and-boosters
#30
JOURNAL ARTICLE
Bethany Girard, Elisabeth Baum-Jones, Rebecca L Best, Thomas W Campbell, Jack Coupart, Kyla Dangerfield, Abhilash Dhal, Michael Jhatro, Brian Martinez, Jack Reifert, John Shon, Minlu Zhang, Rebecca Waitz, Spyros Chalkias, Darin K Edwards, Maha Maglinao, Robert Paris, Rolando Pajon
BACKGROUND: Characterizing the antibody epitope profiles of messenger RNA (mRNA)-based vaccines against SARS-CoV-2 can aid in elucidating the mechanisms underlying the antibody-mediated immune responses elicited by these vaccines. METHODS: This study investigated the distinct antibody epitopes toward the SARS-CoV-2 spike (S) protein targeted after a two-dose primary series of mRNA-1273 followed by a booster dose of mRNA-1273 or a variant-updated vaccine among serum samples from clinical trial adult participants...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38562613/lipid-nanoparticle-based-inhibitors-for-sars-cov-2-host-cell-infection
#31
JOURNAL ARTICLE
Vinith Yathindranath, Nura Safa, Mateusz Marek Tomczyk, Vernon Dolinsky, Donald W Miller
PURPOSE: The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lingering threat to public health has fueled the search for effective therapeutics to treat SARS-CoV-2. This study aimed to develop lipid nanoparticle (LNP) inhibitors of SARS-CoV-2 entry to reduce viral infection in the nose and upper airway. METHODS: Two types of LNP formulations were prepared following a microfluidic mixing method. The LNP-Trap consisted of DOPC, DSPC, cholesterol, and DSPE-PEG-COOH modified with various spike protein binding ligands, including ACE2 peptide, recombinant human ACE2 (rhACE2) or monoclonal antibody to spike protein (mAb)...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38556000/designing-robust-monoclonal-antibody-drug-products-pitfalls-of-simplistic-approaches-for-stability-prediction
#32
JOURNAL ARTICLE
Kelvin B Rembert, Yatin R Gokarn, Atul Saluja
Thermal stability attributes including unfolding onset (Tonset ) and mid-point (Tm ) are often utilized for efficient development of monoclonal antibody (mAb) products during lead selection and formulation screening workflows. An assumption of direct correlation between thermal and kinetic physical stability underpins this basic approach. While literature reports have substantiated this general approach under specific conditions, clear exceptions have been highlighted alongside. Herein, a set of mAbs formulated under diverse solution conditions to generate a broad array of thermal and kinetic stability profiles were systematically analyzed...
March 29, 2024: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38554741/the-search-for-novel-proline-analogs-for-viscosity-reduction-and-stabilization-of-highly-concentrated-monoclonal-antibody-solutions
#33
JOURNAL ARTICLE
Monika Prašnikar, Matic Proj, Maja Bjelošević Žiberna, Blaž Lebar, Benjamin Knez, Nika Kržišnik, Robert Roškar, Stanislav Gobec, Iztok Grabnar, Aleš Žula, Pegi Ahlin Grabnar
Administration of monoclonal antibodies (mAbs) is currently focused on subcutaneous injection associated with increased patient adherence and reduced treatment cost, leading to sustainable healthcare. The main bottleneck is low volume that can be injected, requiring highly concentrated mAb solutions. The latter results in increased solution viscosity with pronounced mAb aggregation propensity because of intensive protein-protein interactions. Small molecule excipients have been proposed to restrict the protein-protein interactions, contributing to reduced viscosity...
March 28, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38547650/development-of-a-platform-method-for-rapid-detection-and-characterization-of-domain-specific-post-translational-modifications-in-bispecific-antibodies
#34
JOURNAL ARTICLE
Sophia Liu, Jennifer B Nguyen, Yimeng Zhao, Svetlana Schussler, Sunnie Kim, Haibo Qiu, Ning Li, Michael P Rosconi, Erica A Pyles
Charge heterogeneity is inherent to all therapeutic antibodies and arises from post-translational modifications (PTMs) and/or protein degradation events that may occur during manufacturing. Among therapeutic antibodies, the bispecific antibody (bsAb) containing two unique Fab arms directed against two different targets presents an additional layer of complexity to the charge profile. In the context of a bsAb, a single domain-specific PTM within one of the Fab domains may be sufficient to compromise target binding and could potentially impact the stability, safety, potency, and efficacy of the drug product...
March 18, 2024: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/38543936/evaluation-of-a-combined-live-attenuated-vaccine-against-lumpy-skin-disease-contagious-bovine-pleuropneumonia-and-rift-valley-fever
#35
JOURNAL ARTICLE
Zohra Bamouh, Amal Elarkam, Soufiane Elmejdoub, Jihane Hamdi, Zineb Boumart, Greg Smith, Matthew Suderman, Mahder Teffera, Hezron Wesonga, Stephen Wilson, Douglas M Watts, Shawn Babiuk, Brad Pickering, Mehdi Elharrak
The use of effective vaccines is among the most important strategies for the prevention and progressive control of transboundary infectious animal diseases. However, the use of vaccine is often impeded by the cost, a lack of cold chains and other factors. In resource-limited countries in Africa, one approach to improve coverage and reduce cost is to vaccinate against multiple diseases using combined vaccines. Therefore, the objective of this study was to evaluate a combined vaccine for the prevention and control of Lumpy Skin Disease (LSD), Contagious Bovine Pleuropneumonia (CBPP) and Rift Valley fever (RVF)...
March 13, 2024: Vaccines
https://read.qxmd.com/read/38543894/mrna-based-vaccines-are-highly-immunogenic-and-confer-protection-in-the-gnotobiotic-pig-model-of-human-rotavirus-diarrhea
#36
JOURNAL ARTICLE
Casey Hensley, Sandro Roier, Peng Zhou, Sofia Schnur, Charlotte Nyblade, Viviana Parreno, Annie Frazier, Maggie Frazier, Kelsey Kiley, Samantha O'Brien, Yu Liang, Bryan T Mayer, Ruizhe Wu, Celia Mahoney, Monica M McNeal, Benjamin Petsch, Susanne Rauch, Lijuan Yuan
Human rotavirus (HRV) is still a leading cause of severe dehydrating gastroenteritis globally, particularly in infants and children. Previously, we demonstrated the immunogenicity of mRNA-based HRV vaccine candidates expressing the viral spike protein VP8* in rodent models. In the present study, we assessed the immunogenicity and protective efficacy of two mRNA-based HRV trivalent vaccine candidates, encoding VP8* of the genotypes P[8], P[6], or P[4], in the gnotobiotic (Gn) pig model of Wa (G1P[8]) HRV infection and diarrhea...
March 1, 2024: Vaccines
https://read.qxmd.com/read/38543871/mrna-therapeutic-vaccine-for-hepatitis-b-demonstrates-immunogenicity-and-efficacy-in-the-aav-hbv-mouse-model
#37
JOURNAL ARTICLE
Dorien De Pooter, Wim Pierson, Soheil Pourshahian, Koen Dockx, Ben De Clerck, Isabel Najera, Heather Davis, Ellen Van Gulck, Daniel Boden
Chronic infection with hepatitis B virus (HBV) develops in millions of patients per year, despite the availability of effective prophylactic vaccines. Patients who resolve acute HBV infection develop HBV-specific polyfunctional T cells accompanied by neutralizing antibodies, while in patients with chronic hepatitis B (CHB), immune cells are dysfunctional and impaired. We describe a lipid nanoparticle (LNP)-formulated mRNA vaccine, optimized for the expression of HBV core, polymerase, and surface (preS2-S) antigens with the aim of inducing an effective immune response in patients with CHB...
February 25, 2024: Vaccines
https://read.qxmd.com/read/38543314/analytical-insights-into-protein-alum-interactions-and-their-impact-on-conformational-epitope
#38
JOURNAL ARTICLE
Alessio Corrado, Mila Toppazzini, Alessandro Vadi, Carmine Malzone, Rosy Galasso, Alessandro Donati, Riccardo De Ricco, Francesco Berti
Several alum-adjuvanted vaccines have been licensed in the past 40 years. Despite its extensive and continuous use, the immune mechanism of action of alum adjuvants is not yet completely understood. Many different variables during the formulation process have been assessed as critical for alum-adjuvanted vaccines, although most of them are still not yet fully understood. The absence of a clear understanding of all the possible variables regulating the mechanism of action and the behavior that alum adjuvant imposes on the protein antigen may also be related to analytical challenges...
March 19, 2024: Pharmaceutics
https://read.qxmd.com/read/38538869/the-2023-guidelines-for-the-management-and-treatment-of-glucocorticoid-induced-osteoporosis
#39
JOURNAL ARTICLE
Yoshiya Tanaka, Satoshi Soen, Shintaro Hirata, Yosuke Okada, Saeko Fujiwara, Ikuko Tanaka, Yuriko Kitajima, Takuo Kubota, Kosuke Ebina, Yuichi Takashi, Reiko Inoue, Mika Yamauchi, Naoaki Okubo, Masanobu Ueno, Yasuhisa Ohata, Nobuaki Ito, Keiichi Ozono, Hisanori Nakayama, Masakazu Terauchi, Sakae Tanaka, Seiji Fukumoto
INTRODUCTION: Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30-50% of patients, and markedly decreases their quality of life. In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) published the revised guidelines for the management and treatment of steroid-induced osteoporosis, providing the treatment criteria based on scores of risk factors, including previous fractures, age, GC doses, and bone mineral density, for patients aged ≥18 years who are receiving GC therapy or scheduled to receive GC therapy for ≥3 months...
March 28, 2024: Journal of Bone and Mineral Metabolism
https://read.qxmd.com/read/38538335/effect-of-lipid-composition-on-the-interaction-of-liposomes-with-thp-1-derived-macrophages
#40
JOURNAL ARTICLE
Ryoya Ibuki, Takashi Tokui, Masaya Kuriyama, Kanji Hosoda, Hiroshi Tomoda, Kumiko Sakai-Kato
Recently, liposomal formulations that target macrophages have been used to treat lung diseases. However, the detailed mechanism of the cellular uptake must be elucidated to identify a formulation with excellent cellular uptake efficiency to treat non-tuberculous mycobacterial lung disease. We studied the effect of lipid composition on the cellular uptake of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)/cholesterol (Chol) liposomes with a size of approximately 200 nm into THP-1-derived macrophages...
2024: Biological & Pharmaceutical Bulletin
keyword
keyword
96236
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.